SGB-3908 / Sanegene Bio, Innovent Biologics - LARVOL DELTA

Safety, Pharmacokinetics, and Pharmacodynamics of SGB-3908, A siRNA Targeting AGT in Healthy and Mildly Hypertensive Subjects (AHA 2025) - "Nighttime SBP/DBP changes were −9.4/-3.3, −7.1/-4.9, −15.1/-10.7, −11.6/-6.7, and −16.0/-12.9 mmHg for Doses 1–5, respectively, versus −5.0/-2.6 mmHg with placebo (Figure 2).ConclusionSGB-3908 demonstrated a favorable safety profile, sustained AGT reduction, and preliminary BP reduction in healthy and mildly hypertensive subjects. These findings support further investigation for hypertension and other indications where RAAS inhibitors are effective, with potential advantages in dosing frequency and adherence."

Clinical • PK/PD data • Cardiovascular • Hypertension • Hypotension • CRP

Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Suzhou Sanegene Bio Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2025 ➔ Jan 2025

Enrollment closed • Trial primary completion date • Cardiovascular • Hypertension

Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Suzhou Sanegene Bio Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension